NCT02407405View on ClinicalTrials.gov

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 7, 2016

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)
Interventions
DRUG

Selumetinib

orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH